

Supplementary files - Cost-effectiveness analysis of 21-valent pneumococcal conjugated vaccine among adults in Canada

Raphael Ximenes, PhD¹, Alison E. Simmons, MPH^{1,2}, Gebremedhin B. Gebretekle, PhD¹, Austin Nam, PhD¹, Eva Wong¹, Marina I. Salvadori^{1,3}, Alyssa R. Golden, PhD⁴, Beate Sander, PhD^{5,6,7,8}, Kyla J. Hildebrand^{9, 10}, Matthew Tunis, PhD¹, and Ashleigh R. Tuite, PhD MPH^{1,2}

¹ Centre for Immunization Surveillance and Programs, Public Health Agency of Canada, Ottawa, ON, Canada

² Dalla Lana School of Public Health, University of Toronto, Toronto, ON, Canada

³ Department of Pediatrics, McGill University, Montreal, QC, Canada

⁴ National Microbiology Laboratory Branch, Public Health Agency of Canada, Winnipeg, MB, Canada

⁵ University Health Network, Toronto, ON, Canada

⁶ Institute of Health Policy, Management and Evaluation (IHPE), University of Toronto, Toronto, ON, Canada

⁷ Public Health Ontario, Toronto, ON, Canada

⁸ ICES, Toronto, ON, Canada

⁹ Department of Pediatrics, Division of Immunology, Faculty of Medicine, University of British Columbia, Vancouver, BC, Canada

¹⁰ British Columbia Children's Hospital Research Institute, Vancouver, BC, Canada

Corresponding author email: raphael.ximenes@phac-aspc.gc.ca

Funding statement:

This research was supported, in part, by a Canada Research Chair in Economics of Infectious Diseases held by Beate Sander (CRC-2022-00362).

Keywords: Pneumococcal, Invasive pneumococcal disease; Vaccines, PCV20, PCV21, Cost-effectiveness, High risk populations, health economic modeling

Appendix A. Supplementary Material

Supplementary Methods: Age- and region-specific incidence data for IPD were obtained from the International Circumpolar Surveillance program and the Canadian Notifiable Disease Surveillance System (1, 2). The model accounts for regional variations, such as significantly higher incidence of IPD and CAP in Northern Canada compared to the rest of the country. The serotype distribution by age group was obtained from The Public Health Agency of Canada's National Microbiology Laboratory [PHAC-NML] (3). Serotypes were then categorized into distinct groups based on vaccine coverage. We classified serotypes covered by multiple vaccines and identified those unique to specific vaccines.

Data on age-specific inpatient CAP incidence were obtained from the Discharge Abstract Database (DAD) (4). The relative risk of PD in higher-risk populations (5-8), as well as estimates of case fatality (9, 10) and the risk of long term-sequelae (11-13) were obtained from the literature. Duration of vaccine protection was accounted for with a 15-year time horizon for the conjugate vaccine, assuming stable effectiveness for the first 5 years, followed by a linear decline in effectiveness, reaching zero by the end of the 15-year period. (11-13).

The costs associated with IPD and pneumonia-related hospitalizations were estimated using Resource Intensity Weights obtained from the Discharge Abstract Database (4). Hospitalization costs for IPD and CAP were adjusted for different age groups and regions, taking into account the higher healthcare costs in Northern Canada (14-18). The model also considered non-medical costs, such as transportation, which can be substantial in remote areas (4, 19-27). Additionally, indirect costs, such as lost productivity and caregiver burden (28-30), were included in the economic analysis for the societal perspective.

Table S1. Epidemiologic parameters

Parameter	Base	Range	Reference	
IPD incidence (per 100,000)				
18-49 years				
Northern Canada ^a	11.2	8.4 – 14.0*	Canadian Notifiable Disease System (CNDSS) 2018-2019; International Circumpolar Surveillance (ICS) program 2018-2019 (1, 2)	
Rest of Canada	5.2	3.9 – 6.5*		
50-64 years				
Northern Canada	38.97	23.10 – 58.93		
Rest of Canada	14.45	13.83 – 15.09		
65-74 years				
Northern Canada	71.30	34.20 – 121.79		
Rest of Canada	20.61	19.52 – 21.72		
75+ years				
Northern Canada	105.01	38.55 – 204.12		
Rest of Canada	31.06	29.51 – 32.65		
Inpatient CAP incidence (per 100,000)				
18-49 years				
Northern Canada	167.37	143.86 – 190.88		DAD 2018-2019 (4)
Rest of Canada	90.60	89.42 – 91.78		
50-64 years				
Northern Canada	568.81	500.44 – 637.18		
Rest of Canada	347.81	344.45 – 351.16		
65-74 years				
Northern Canada	1,777.32	1,562.12 – 1,992.51		
Rest of Canada	871.48	863.79 – 879.18		
75+ years				
Northern Canada	5,104.13	4,540.99 – 5,667.28		
Rest of Canada	2,845.89	2,829.82 – 2,861.95		
Relative risk of PD in higher risk populations				
Experiencing homelessness	50	27 – 72	Tyrell et al., 2021; Plevnesi et al., 2009; Shariatzadeh et al., 2005; Steinberg et al., 2023 (31-34)	
18-64 years				
Chronic medical condition	4	3 – 6	Shigayeva et al., 2022 (5)	
Immunocompromising condition	34	21 – 55		
65+ years				
Chronic medical condition	1.7	1.0 – 2.5	Shigayeva et al., 2022 (5)	
Immunocompromising condition	4.3	2.5 – 7.4		
Proportion of CAP cases managed in inpatient setting (%)^c				
18-49 years	3.27	0.69 – 5.86	O'Reilly et al., 2023 (14)	
50-64 years	15.10	12.80 – 17.40		
65-74 years	24.76	22.66 – 26.85		
75+ years	32.65	30.53 – 34.76		
Proportion of CAP cases attributed to <i>S. pneumoniae</i> (%)^d				
18-49 years	19.5	14.6 – 24.4*	LeBlanc et al., 2022 (6)	
50+ years	18.0	8.0 – 24.0	Lansbury et al., 2022; LeBlanc et al., 2022 (6, 35)	
Proportion of IPD cases with meningitis (%)				

18-64 years	7.0	5.3 – 8.8*	Backhaus et al., 2016 (9)
65+ years	5.0	3.8 – 6.3*	
Proportion of IPD cases with meningitis who experience post-meningitis sequelae (%)			
Neurologic sequelae ^e	12.2	5.3 – 19.1	Jit, 2010 (10)
Auditory sequelae ^f	20.9	17.1 – 24.7	
Case fatality (%)			
IPD			
18-49 years	5.7	4.9 – 6.6	Wijayasri et al., 2019 (7)
50-64 years	10.9	9.9 – 12.0	
65+ years	17.2	16.2 – 18.3	
Inpatient pCAP			
16-49 years	3.8	1.4 – 6.2	LeBlanc et al., 2022 (6)
50-64 years	4.8	2.7 – 6.9	
65+ years	9.9	7.5 – 12.2	
Relative risk of death from PD in higher risk population			
Chronic medical condition	1.5		Shigayeva et al., 2022 (5)
Immunocompromising condition	1.9		Shigayeva et al., 2016 (8)

Notes: IPD = invasive pneumococcal disease; CAP = community acquired pneumonia.

^a Values for Northern Canada were calculated by adjusting estimates for the Rest of Canada with multipliers (i.e., 2.15) extracted from the Canadian Notifiable Disease System (CNDSS) 2018-2019 and International Circumpolar Surveillance (ICS) program 2018-2019 (1, 2)

^b Parameters were derived using polynomial regression.

^d Proportion of CAP cases among hospitalized adults where *S. pneumoniae* was detected from blood culture, sputum culture, or urine antigen detection

^e Cranial nerve palsies

^f Hearing loss

* Range defined as $\pm 25\%$ of the base value

Table S2. Vaccine parameters

Parameter	Base	Range	Reference
Vaccination coverage (%)			
18-49 years	21.2	19.1 – 23.5	Government of Canada, 2024 (36)
50-64 years	28.8	26.5 – 31.1	
65-79 years	54.0	51.9 – 56.0	
With chronic medical conditions (including immunocompromising conditions)			
18-49 years	24.3	21.6 – 27.3	Government of Canada, 2024 (36)
50-64 years	33.4	30.8 – 36.2	
65-79 years	60.7	57.7 – 63.7	
80+ years	65.6	56.1 – 74.0	
Vaccine effectiveness			
Pneu-C at age 65 (%)			
VT-IPD	88	61 – 98	van Werkhoven et al., 2015 (12)
ST3-IPD	53	0 – 80	Lewis et al., 2019; Farrar et al., 2023 (37, 38)
VT-pCAP	68	39 – 85	van Werkhoven et al., 2015 (12)
ST3-pCAP	16	0 – 32	Stoecker, 2024 (39)
Pneu-P at age 65 (%)			
VT-IPD	52	36 – 64	Farrar et al., 2023 (37)
ST3-IPD	2	0 – 21	Djennad et al., 2018 (40)
VT-pCAP	26	0 – 49	Farrar et al., 2023 (37)
ST3-pCAP	2	0 – 21	Assumption
Pneu-C in adults with chronic medical conditions (%)			
VT-IPD	75	41 – 98	Bonten et al., 2014; van Werkhoven et al., 2015; Stoecker, 2024 (12, 41, 42)
ST3-IPD	26	0 – 53	Stoecker, 2024 (39)
VT-pCAP	40	11 – 60	Suaya et al., 2018 (43)
ST3-pCAP	16	0 – 32	Stoecker, 2024 (39)
Pneu-C in adults with immunocompromising conditions (%)			
VT-IPD	67	0 – 99	Bonten et al., 2014 (41)
ST3-IPD	9	0 – 18	Stoecker, 2024 (39)
VT-pCAP	15	5 – 22	Stoecker, 2024 (39)
ST3-pCAP	5	0 – 11	Stoecker, 2024 (39)
Duration of protection			
Pneu-C	15 years: stable for 5 years, linear decline to 0 over 10 years		Leidner, 2021; Patterson et al., 2016; van Werkhoven et al., 2015 (11-13)
Pneu-P	15 years: linear decline to 0 over 15 years		Leidner, 2021 (11)

Notes: Pneu-C = pneumococcal conjugate vaccine; Pneu-P = pneumococcal polysaccharide vaccine; VT = vaccine-type serotypes; ST3 = serotype 3.

Table S3. Direct and indirect cost parameters

Parameter	Base	Range	Reference	
Cost per dose of vaccine (\$)				
Vaccine administration	18	13 – 22	O’Reilly et al., 2017 (44)	
PCV-20	109.91		Pfizer (45)	
PCV-21	129.90		Merck (46)	
PPV-23	35.24		Merck (46)	
Cost per inpatient IPD case (\$)				
18-49 years	30,440	28,059 – 32,915	DAD 2015-2019 (15-18)	
50-64 years	30,793	28,909 – 32,735		
65-74 years	30,590	28,237 – 33,038		
75+ years	22,716	21,131 – 24,357		
Cost per inpatient CAP case (\$)				
18-64 years				
Northern Canada ^a	17,906	17,305 – 18,538	O’Reilly et al., 2023 (14)	
Rest of Canada	14,986	14,483 – 15,515		
65+ years				
Northern Canada ^a	15,436	15,167 – 15,713		
Rest of Canada	14,980	14,718 – 15,248		
Cost per outpatient CAP case (\$)				
18-64 years	1,255	1,219 – 1,290	O’Reilly et al., 2023 (14)	
65+ years	3,531	3,469 – 3,592		
Cost of care for patients with post-meningitis sequelae per year (\$)				
Annual cost of care for those with auditory sequelae ^b	3,183	2,387 – 3,979*	Christensen et al., 2014 (47)	
Annual cost of care for those with neurologic sequelae ^c	10,593	7,945 – 13,241*		
Cost of medication, out-of-pocket (\$)				
18-64 years	19.08	14.32 – 28.86	Ontario Drug Benefit (48)	
65+ years	0			
Cost of transportation, health system (\$)				
Inpatient				
Northern Canada	8,001	3,171 – 12,887	DAD 2018-2019; Glauser et al., 2015; Government of Northwest Territories 2018; Government of Nunavut; Rendell, 2016; Tam et al., 2009 (4, 19-23)	
Rest of Canada	418	210 – 626	DAD 2018-2019; Glauser et al., 2015; Government of Nunavut; Rendell, 2016 (4, 19, 21, 22)	
Outpatient				
Northern Canada	129	97 – 161	Government of Yukon; Pong and Pitblado, 2005 (24, 25)	
Rest of Canada	0		Assumed to be out-of-pocket	
Cost of transportation, out-of-pocket (\$)				
Inpatient				
Northern Canada	153	75 – 405	DAD 2018-2019; Glauser et al., 2015; Government of Nunavut; Rendell, 2016 (4, 19, 21, 22)	

Rest of Canada	89	53 – 128	DAD 2018-2019; CRA 2022; Colbert 2020 (4, 26, 27)
Outpatient			
Northern Canada	149	112 – 186*	Government of Yukon; Pong and Pitblado, 2005; CRA 2022 (24-26)
Rest of Canada	4	3 – 5*	Pong and Pitblado, 2005; CRA 2022 (25, 26)
Parking	16	0 – 32	Assumption
Daily cost of travel subsidy for overnight stay, health system (\$)			
Northern Canada	164	82 – 327	Government of Yukon (24)
Rest of Canada	0		
Mean annual income (\$)			
18-49 years ^d	57,423		Statistics Canada (49)
50-64 years ^e	80,810		
65+ years	50,741		
Mean hourly caregiver income (\$)			
All ages	28.67	24.64 – 37.89	Hollander et al., 2009 (28)
Work time lost (days)			
Inpatient IPD or CAP	14.6	8.8 – 28.2	Pasquale et al. 2019 (50)
Outpatient CAP	5.4	1.8 – 6.3	
Visit health care provider for vaccination	0.5		Assumption
Reduction in employment due to post-meningitis sequelae (%)			
Auditory sequelae	25	15 – 35	Assumption used for lower estimate; Bizier et al., 2016; Jiang et al., 2012 (51, 52)
Neurologic sequelae	98	75 – 100	Assumption; Jiang et al., 2012 (52)
Caregiver time lost (hours)			
Inpatient IPD or CAP	40.65	11.63 – 81.30	Wyrwich et al., 2015 (29)
Neurologic sequelae	5,660	4,245 – 7,075*	Ganapathy et al., 2015 (30)

Notes: Costs were converted to Canadian dollars using purchasing power parities from the Organisation for Economic Co-operation and Development and inflated to 2023 dollars using the Canadian Consumer Price Index. Product-specific values were used for health-related costs and transportation costs.

^a Values for Northern Canada were calculated by adjusting estimates for the Rest of Canada with multipliers extracted from the Discharge Abstract Database 2015-2019 (15-18)

^b The annual cost for auditory sequelae reflects the annual cost The shifting epidemiology and serotype distribution of invasive pneumococcal disease in Ontario, Canada, 2007-2017 of minor post-meningitis sequelae.

^c The annual cost of neurologic sequelae reflects the annual cost of severe post-meningitis sequelae.

^d Median total income in 2022 CAD, inflated to 2023 CAD, for 25 to 34 years of age

^e Median total income in 2022 CAD, inflated to 2023 CAD, for 45 to 54 years of age

* Range defined as $\pm 25\%$ of the base value

Table S4. Health utilities

Parameter	Base	Range	Reference
Background health utility			
18-49 years	0.873	0.857 – 0.89	Yan et al., 2023 (53)
50-64 years	0.847	0.83 – 0.864	
65-74 years	0.867	0.849 – 0.885	
75+ years	0.861	0.835 – 0.887	
Average background health utility			
Chronic medical or immunocompromising condition ^a	0.836		
No chronic medical or immunocompromising condition	0.899		
IPD and pCAP utility multipliers			
Hospitalization	0.8659	0.8323 – 0.8963	Mangen et al., 2017 (54)
Outpatient CAP	0.9938	0.9917 – 0.9956	Oppong et al., 2013a; Oppong et al., 2013b (55, 56)
Auditory Sequelae	0.6850	0.6214 – 0.7451	Galante et al., 2011 (57)
Neurologic Sequelae	0.3441	0.2725 – 0.4164	Galante et al., 2011 (57)

^a We assumed this background health utility also applies to individuals experiencing homelessness

Table S1. Mean Costs, QALYs, and ICERs for pneumococcal vaccination of adults aged 65 years and older at average risk of IPD, from health system and societal perspectives (per 100,000 population)

Serotype distribution data year	Indirect effects assumption	Rest of Canada				Northern Canada			
		Strategies	Costs (\$)	QALYs	Sequential ICER	Strategies	Costs (\$)	QALYs	Sequential ICER
Health system perspective									
2022	No indirect Effects	PCV21	127,406,265	1,378,631	---	PCV21	260,578,720	1,173,753	---
		PCV20	129,647,781	1,378,472	Dominated	PCV20	268,584,936	1,173,461	Dominated
	Indirect Effects from PCV15	PCV21	127,564,622	1,378,624	---	PCV21	260,999,450	1,173,741	---
		PCV20	130,121,939	1,378,451	Dominated	PCV20	269,842,046	1,173,423	Dominated
	Indirect Effects from PCV20	PCV21	127,821,235	1,378,613	---	PCV21	261,681,134	1,173,720	---
		PCV20	130,890,091	1,378,416	Dominated	PCV20	271,877,732	1,173,362	Dominated
2015-2019	No indirect Effects	PCV21	126,356,529	1,378,682	---	PCV21	257,733,767	1,173,844	---
		PCV20	129,975,821	1,378,456	Dominated	PCV20	269,522,644	1,173,430	Dominated
	Indirect Effects from PCV15	PCV21	126,536,703	1,378,673	---	PCV21	258,212,761	1,173,829	---
		PCV20	130,514,889	1,378,432	Dominated	PCV20	270,951,520	1,173,387	Dominated
	Indirect Effects from PCV20	PCV21	126,808,856	1,378,661	---	PCV21	258,936,168	1,173,808	---
		PCV20	131,328,910	1,378,395	Dominated	PCV20	273,108,195	1,173,322	Dominated
Societal perspective									
2022	No indirect Effects	PCV21	164,786,256	1,378,631	---	PCV21	321,415,627	1,173,753	---
		PCV20	168,082,639	1,378,472	Dominated	PCV20	331,911,406	1,173,461	Dominated
	Indirect Effects from PCV15	PCV21	164,993,185	1,378,624	---	PCV21	321,946,568	1,173,741	---
		PCV20	168,702,229	1,378,451	Dominated	PCV20	333,497,831	1,173,423	Dominated
	Indirect Effects from PCV20	PCV21	165,328,503	1,378,613	---	PCV21	322,806,819	1,173,720	---
		PCV20	169,705,986	1,378,416	Dominated	PCV20	336,066,804	1,173,362	Dominated
2015-2019	No indirect Effects	PCV21	163,414,965	1,378,682	---	PCV21	317,823,008	1,173,844	---
		PCV20	168,528,715	1,378,456	Dominated	PCV20	333,139,604	1,173,430	Dominated
	Indirect Effects from PCV15	PCV21	163,650,399	1,378,673	---	PCV21	318,427,470	1,173,829	---
		PCV20	169,233,122	1,378,432	Dominated	PCV20	334,942,787	1,173,387	Dominated
	Indirect Effects from PCV20	PCV21	164,006,022	1,378,661	---	PCV21	319,340,367	1,173,808	---
		PCV20	170,296,818	1,378,395	Dominated	PCV20	337,664,437	1,173,322	Dominated

Table S2. Mean Costs, QALYs, and ICERs for pneumococcal vaccination of adults aged 50 years at average risk of IPD, from health system and societal perspectives (per 100,000 population)

Serotype distribution data year	Indirect effects assumption	Rest of Canada				Northern Canada				
		Strategies	Costs (\$)	QALYs	Sequential ICER	Strategies	Costs (\$)	QALYs	Sequential ICER	
Health system perspective										
2022	No indirect Effects	No vaccine	121,709,132	2,099,334	---	PCV20	266,005,115	1,892,721	---	
		PCV20	123,337,835	2,099,437	15,840	PCV21	266,563,217	1,892,721	1,765,679	
		PCV21	123,901,032	2,099,437	3,246,243	No vaccine	267,888,430	1,892,530	Dominated by PCV20	
	Indirect Effects from PCV15	No vaccine	121,709,132	2,099,334	---	PCV20	266,138,328	1,892,717	---	
		PCV20	123,386,599	2,099,434	16,704	PCV21	266,607,624	1,892,720	145,953	
		PCV21	123,917,288	2,099,436	299,422	No vaccine	267,888,430	1,892,530	Dominated by PCV20	
	Indirect Effects from PCV20	No vaccine	121,709,132	2,099,334	---	PCV20	266,669,455	1,892,699	---	
		PCV20	123,581,051	2,099,425	20,604	PCV21	266,784,721	1,892,714	7,802	
		PCV21	123,982,116	2,099,433	49,201	No vaccine	267,888,430	1,892,530	Dominated by PCV20	
	2015-2019	No indirect Effects	No vaccine	121,709,132	2,099,334	---	PCV21	265,299,501	1,892,764	---
			PCV21	123,437,274	2,099,460	13,662	No Vaccine	267,888,430	1,892,530	Dominated by PCV20
			PCV20	123,526,358	2,099,427	Dominated by PCV21	PCV20	266,530,502	1,892,702	Dominated by PCV21
Indirect Effects from PCV15		No vaccine	121,709,132	2,099,334	---	PCV21	265,388,371	1,892,761	---	
		PCV21	123,469,789	2,099,459	14,098	No Vaccine	267,888,430	1,892,530	Dominated by PCV20	
		PCV20	123,623,802	2,099,422	Dominated by PCV21	PCV20	266,796,638	1,892,694	Dominated by PCV21	

	Indirect Effects from PCV20	No vaccine	121,709,132	2,099,334	---	PCV21	265,572,690	1,892,755	---
		PCV21	123,537,230	2,099,455	15,037	No Vaccine	267,888,430	1,892,530	Dominated by PCV20
		PCV20	123,825,880	2,099,412	Dominated by PCV21	PCV20	267,348,446	1,892,676	Dominated by PCV21
Societal perspective									
2022	No indirect Effects	No vaccine	161,968,709	2,099,334	---	No vaccine	343,080,452	1,892,530	---
		PCV20	173,493,328	2,099,437	112,084	PCV20	349,569,706	1,892,721	34,016
		PCV21	174,054,200	2,099,437	3,250,765	PCV21	350,122,989	1,892,721	1,750,430
	Indirect Effects from PCV15	No vaccine	161,968,703	2,099,334	---	No vaccine	343,080,452	1,892,530	---
		PCV20	173,574,903	2,099,434	115,575	PCV20	349,770,210	1,892,717	35,885
		PCV21	174,081,392	2,099,436	285,769	PCV21	350,189,827	1,892,720	130,503
	Indirect Effects from PCV20	No vaccine	161,968,703	2,099,334		No vaccine	343,080,452	1,892,530	---
		PCV21	174,189,842	2,099,433	123,442	PCV21	350,456,380	1,892,714	40,118
		PCV20	173,900,196	2,099,425	Extendedly dominated	PCV20	350,569,624	1,892,699	Dominated by PCV21
2015-2019	No indirect Effects	No vaccine	161,968,703	2,099,334	---	No vaccine	343,080,452	1,892,530	---
		PCV21	173,275,973	2,099,460	89,392	PCV21	348,213,134	1,892,764	21,971
		PCV20	173,816,232	2,099,427	Dominated by PCV21	PCV20	350,379,417	1,894,702	Dominated by PCV21
	Indirect Effects from PCV15	No vaccine	161,968,703	2,099,334	---	No vaccine	343,080,452	1,892,530	---
		PCV21	173,330,365	2,099,459	90,973	PCV21	348,346,893	1,892,761	22,827
		PCV20	173,979,242	2,099,422	Dominated by PCV21	PCV20	350,779,983	1,892,694	Dominated by PCV21
	Indirect Effects from PCV20	No vaccine	161,968,703	2,099,334	---	No vaccine	343,080,452	1,892,530	---
		PCV21	173,443,184	2,099,455	94,385	PCV21	348,624,316	1,892,755	24,673
		PCV20	174,317,292	2,099,412	Dominated by PCV21	PCV20	351,610,525	1,892,676	Dominated by PCV21

Table S3. Mean Costs, QALYs, and ICERs for pneumococcal vaccination of adults aged 50 years with immunocompromising conditions (RR = 34), from health system and societal perspectives (per 100,000 population)

Serotype distribution data year	Indirect effects assumption	Rest of Canada			
		Strategies	Costs	QALYs	Sequential ICER
Health system perspective					
2022	No indirect Effects	PCV20	2,257,012,222	1,691,426	
		PCV21	2,257,633,083	1,691,428	341,785
	Indirect Effects from PCV15	PCV20	2,257,554,999	1,691,400	
		PCV21	2,257,814,057	1,691,419	13,149
	Indirect Effects from PCV20	PCV21	2,258,535,466	1,691,384	
		PCV20	2,259,716,210	1,691,294	Dominated
2015-2019	No indirect Effects	PCV21	2,252,167,757	1,691,708	
		PCV20	2,259,024,960	1,691,325	Dominated
	Indirect Effects from PCV15	PCV21	2,252,531,488	1,691,690	
		PCV20	2,260,107,271	1,691,272	Dominated
	Indirect Effects from PCV20	PCV21	2,253,285,471	1,691,653	
		PCV20	2,262,347,702	1,691,168	Dominated
Societal perspective					
2022	No indirect Effects	PCV20	3,073,396,106	1,691,426	
		PCV21	3,073,984,363	1,691,428	298,254
	Indirect Effects from PCV15	PCV21	3,074,312,419	1,691,419	
		PCV20	3,074,380,015	1,691,400	Dominated
	Indirect Effects from PCV20	PCV21	3,075,620,142	1,691,384	
		PCV20	3,078,297,772	1,691,294	Dominated
2015-2019	No indirect Effects	PCV21	3,063,886,165	1,691,708	
		PCV20	3,077,078,915	1,691,325	Dominated
	Indirect Effects from PCV15	PCV21	3,064,545,499	1,691,690	
		PCV20	3,079,040,883	1,691,272	Dominated
	Indirect Effects from PCV20	PCV21	3,065,912,251	1,691,653	
		PCV20	3,083,102,328	1,691,162	Dominated

Table S4. Mean Costs, QALYs, and ICERs for pneumococcal vaccination of adults aged 50 years with chronic medical conditions (RR = 4), from health system and societal perspectives (per 100,000 population)

Serotype distribution data year	Indirect effects assumption	Rest of Canada			
		Strategies	Costs	QALYs	Sequential ICER
Health system perspective					
2022	No indirect Effects	PCV20	464,680,848	2,011,123	
		PCV21	465,328,641	2,011,124	1,225,461
	Indirect Effects from PCV15	PCV20	464,826,930	2,011,116	
		PCV21	465,377,339	2,011,121	101,313
	Indirect Effects from PCV20	PCV20	465,409,270	2,011,086	
		PCV21	465,571,537	2,011,111	6,496
2015-2019	No indirect Effects	PCV21	463,943,832	2,011,196	
		PCV20	465,256,927	2,011,093	Dominated by PCV21
	Indirect Effects from PCV15	PCV21	464,041,335	2,011,191	
		PCV20	465,548,697	2,011,078	Dominated by PCV21
	Indirect Effects from PCV20	PCV21	464,234,548	2,011,181	
		PCV20	466,153,537	2,011,048	Dominated by PCV21
Societal perspective					
2022	No indirect Effects	PCV20	627,198,060	2,011,123	
		PCV21	627,838,260	2,011,124	1,211,098
	Indirect Effects from PCV15	PCV20	627,450,550	2,011,116	
		PCV21	627,922,431	2,011,121	86,858
	Indirect Effects from PCV20	PCV21	628,258,085	2,011,111	
		PCV20	628,457,079	2,011,086	Dominated by PCV21
2015-2019	No indirect Effects	PCV21	625,416,503	2,011,196	
		PCV20	628,203,078	2,011,093	Dominated by PCV21
	Indirect Effects from PCV15	PCV21	625,585,072	2,011,191	
		PCV20	628,707,380	2,011,078	Dominated by PCV21
	Indirect Effects from PCV20	PCV21	625,934,531	2,011,181	
		PCV20	629,752,807	2,011,048	Dominated by PCV21

Table S9. Mean Costs, QALYs, and ICERs for pneumococcal vaccination of adults aged 50 years who are unhoused populations (RR = 50), from health system and societal perspectives (per 100,000 population)

Serotype distribution data year	Indirect effects assumption	Rest of Canada			
		Strategies	Costs	QALYs	Sequential ICER

Health system perspective					
2022	No indirect Effects	PCV20	3,357,617,681	1,830,102	
		PCV21	3,357,063,583	1,830,108	74,501
	Indirect Effects from PCV15	PCV21	3,358,625,104	1,830,081	
		PCV20	3,359,299,737	1,830,021	Dominated
	Indirect Effects from PCV20	PCV21	3,360,857,668	1,829,974	
		PCV20	3,365,945,589	1,829,704	Dominated
2015-2019	No indirect Effects	PCV21	3,341,262,194	1,830,933	
		PCV20	3,364,334,167	1,829,761	Dominated
	Indirect Effects from PCV15	PCV21	3,342,419,325	1,830,878	
		PCV20	3,367,650,150	1,829,603	Dominated
	Indirect Effects from PCV20	PCV21	3,344,810,135	1,830,764	
		PCV20	3,374,449,818	1,829,278	Dominated
Societal perspective					
2022	No indirect Effects	PCV20	4,574,652,469	1,830,102	
		PCV21	4,575,010,814	1,830,108	59,872
	Indirect Effects from PCV15	PCV21	4,575,970,943	1,830,081	
		PCV20	4,577,528,595	1,830,021	Dominated
	Indirect Effects from PCV20	PCV21	4,579,788,418	1,829,974	
		PCV20	4,588,892,948	1,829,704	Dominated
2015-2019	No indirect Effects	PCV21	4,546,225,581	1,830,933	
		PCV20	4,586,441,928	1,829,761	Dominated
	Indirect Effects from PCV15	PCV21	4,548,203,759	1,830,878	
		PCV20	4,592,111,670	1,829,603	Dominated
	Indirect Effects from PCV20	PCV21	4,552,291,082	1,830,764	
		PCV20	4,651,061,119	1,827,856	Dominated

Table S10. Mean Costs, QALYs, and ICERs for pneumococcal vaccination of adults aged 33 years with immunocompromising conditions (RR = 34), from health system and societal perspectives (per 100,000 population)

Serotype distribution data year	Indirect effects assumption	Rest of Canada			
		Strategies	Costs	QALYs	Sequential ICER
Health system perspective					

2022	No indirect Effects	PCV20	1,952,943,411	2,349,621	
		PCV21	1,955,332,320	2,349,561	Dominated by PCV20
	Indirect Effects from PCV15	PCV20	1,953,119,872	2,349,616	
		PCV21	1,955,390,815	2,349,560	Dominated by PCV20
	Indirect Effects from PCV20	PCV20	1,954,039,509	2,349,588	
		PCV21	1,955,696,079	2,349,550	Dominated by PCV20
2015-2019	No indirect Effects	PCV21	1,953,582,595	2,349,616	
		PCV20	1,953,977,126	2,349,589	Dominated by PCV21
	Indirect Effects from PCV15	PCV21	1,953,681,391	2,349,613	
		PCV20	1,954,272,626	2,349,580	Dominated by PCV21
	Indirect Effects from PCV20	PCV21	1,954,008,945	2,349,603	
		PCV20	1,955,250,791	2,349,550	Dominated by PCV21
Societal perspective					
2022	No indirect Effects	PCV20	2,810,495,976	2,349,621	
		PCV21	2,814,712,764	2,349,561	Dominated by PCV20
	Indirect Effects from PCV15	PCV20	2,810,838,311	2,349,616	
		PCV21	2,814,826,251	2,349,560	Dominated by PCV20
	Indirect Effects from PCV20	PCV20	2,812,622,461	2,349,588	
		PCV21	2,815,418,503	2,349,550	Dominated by PCV20
2015-2019	No indirect Effects	PCV21	2,811,288,383	2,349,616	
		PCV20	2,812,517,337	2,349,589	Dominated by PCV21
	Indirect Effects from PCV15	PCV21	2,811,480,049	2,349,613	
		PCV20	2,813,090,629	2,349,580	Dominated by PCV21
	Indirect Effects from PCV20	PCV21	2,812,115,513	2,349,603	
		PCV20	2,814,988,400	2,349,550	Dominated by PCV21

Table S11. Mean Costs, QALYs, and ICERs for pneumococcal vaccination of adults aged 18-49 years with chronic medical conditions (RR = 4), from health system and societal perspectives (per 100,000 population)

Serotype distribution data year	Indirect effects assumption	Rest of Canada			
		Strategies	Costs	QALYs	Sequential ICER
Health system perspective					
2022	No indirect Effects	No vaccine	352,745,598	2,585,328	
		PCV20	352,907,400	2,585,406	2,084
		PCV21	353,960,132	2,585,391	Dominated by PCV20

	Indirect Effects from PCV15	No Vaccine	352,745,598	2,585,328	
		PCV20	352,961,329	2,585,405	2,830
		PCV21	353,978,069	2,585,390	Dominated by PCV20
	Indirect Effects from PCV20	No vaccine	352,745,598	2,585,328	
		PCV20	353,242,727	2,585,397	7,217
		PCV21	354,071,715	2,585,388	Dominated by PCV20
2015-2019	No indirect Effects	No vaccine	352,745,598	2,585,328	
		PCV20	353,218,349	2,585,398	6,820
		PCV21	353,436,472	2,585,405	31,219
	Indirect Effects from PCV15	No vaccine	352,745,598	2,585,328	
		PCV20	353,308,840	2,585,395	8,412
		PCV21	353,466,671	2,585,404	18,442
	Indirect Effects from PCV20	No vaccine	352,745,328	2,585,328	
		PCV21	353,566,843	2,585,401	11,264
		PCV20	353,608,817	2,585,388	Dominated by PCV21
Societal perspective					
2022	No indirect Effects	No vaccine	494,791,536	2,585,328	
		PCV20	500,772,943	2,585,406	77,056
		PCV21	502,283,380	2,585,391	Dominated by PCV20
	Indirect Effects from PCV15	No vaccine	494,791,536	2,585,328	
		PCV20	500,869,469	2,585,405	79,743
		PCV21	502,315,486	2,585,390	Dominated by PCV20
	Indirect Effects from PCV20	No vaccine	494,791,536	2,585,328	
		PCV20	501,373,148	2,585,397	95,544
		PCV21	502,483,107	2,585,388	Dominated by PCV20
2015-2019	No indirect Effects	No vaccine	494,791,536	2,585,328	
		PCV21	501,341,472	2,585,405	85,840
		PCV20	501,332,149	2,585,398	Extendedly dominated
	Indirect Effects from PCV15	No vaccine	494,791,536	2,585,328	
		PCV21	501,395,525	2,585,404	87,450
		PCV20	501,494,121	2,585,395	Dominated by PCV21
	Indirect Effects from PCV20	No vaccine	494,791,536	2,585,328	
		PCV21	501,574,824	2,585,401	93,040
		PCV20	502,031,063	2,585,388	Dominated by PCV21

Table S12. Mean Costs, QALYs, and ICERs for pneumococcal vaccination of adults aged 18-49 years of unhoused population (RR = 50), from health system and societal perspectives (per 100,000 population)

Serotype distribution data year	Indirect effects assumption	Rest of Canada			
		Strategies	Costs	QALYs	Sequential ICER
Health system perspective					
2022	No indirect Effects	PCV20	2,841,894,983	2,459,641	
		No vaccine	2,873,179,021	2,458,780	Dominated by PCV21
		PCV21	2,849,561,000	2,459,460	Dominated by PCV20
	Indirect Effects from PCV15	PCV20	2,842,566,191	2,459,625	
		No vaccine	2,873,179,021	2,458,780	Dominated by PCV21
		PCV21	2,849,776,632	2,459,455	Dominated by PCV20
	Indirect Effects from PCV20	PCV20	2,846,023,666	2,459,541	
		No vaccine	2,873,179,021	2,458,780	Dominated by PCV21
		PCV21	2,850,897,847	2,459,428	Dominated by PCV20
2015-2019	No indirect Effects	PCV21	2,842,942,021	2,459,625	
		No vaccine	2,873,179,021	2,458,780	Dominated by PCV20
		PCV20	2,845,853,567	2,459,542	Dominated by PCV21
	Indirect Effects from PCV15	PCV21	2,843,317,086	2,459,616	
		No vaccine	2,873,179,021	2,458,780	Dominated by PCV20
		PCV20	2,846,956,209	2,459,516	Dominated by PCV21
	Indirect Effects from PCV20	PCV21	2,844,554,773	2,459,586	
		No vaccine	2,873,179,021	2,458,780	Dominated by PCV20
		PCV20	2,850,559,449	2,459,428	Dominated by PCV21
Societal perspective					
2022	No indirect Effects	PCV20	4,085,198,206	2,459,641	
		No vaccine	4,134,168,120	2,458,780	Dominated by PCV21
		PCV21	4,098,316,594	2,459,460	Dominated by PCV20
	Indirect Effects from PCV15	PCV20	4,086,369,518	2,459,625	
		No vaccine	4,134,168,120	2,458,780	Dominated by PCV21
		PCV21	4,098,692,974	2,459,455	Dominated by PCV20
	Indirect Effects from PCV20	PCV20	4,092,403,889	2,459,541	
		No vaccine	4,134,168,120	2,458,780	Dominated by PCV21
		PCV21	4,100,650,063	2,459,428	Dominated by PCV20
	No indirect Effects	PCV21	4,086,724,549	2,459,625	

2015-2019		No vaccine	4,134,168,120	2,458,780	Dominated by PCV20
		PCV20	4,092,140,500	2,459,542	Dominated by PCV21
	Indirect Effects from PCV15	PCV21	4,087,379,064	2,459,616	
		No vaccine	4,134,168,120	2,458,780	Dominated by PCV20
	Indirect Effects from PCV20	PCV20	4,094,065,015	2,459,516	Dominated by PCV21
		PCV21	4,089,539,079	2,459,586	
		No vaccine	4,134,168,120	2,458,780	Dominated by PCV20
		PCV20	4,100,354,503	2,459,428	Dominated by PCV21

References

1. Public Health Agency of Canada. IPD in Canada, 2011-2020. 2022.
2. National Advisory Committee on Immunization. Public health level recommendations on the use of pneumococcal vaccines in adults, including the use of 15-valent and 20-valent conjugate vaccines. Ottawa (ON): Public Health Agency of Canada; 2023.
3. PHAC-NML. Annual counts of vaccine serotypes by age group, 2011-2023 (Unpublished data, Personal communication). Public Health Agency of Canada's National Microbiology Laboratory. 2024.
4. Canadian Institute for Health Information. Discharge Abstract Database 2015-2019 [Accessed March 3, 2022].
5. Shigayeva A, Chung H, Kwong JC, Demczuk WH, Martin I, Almorhi H, et al. Burden of Invasive Pneumococcal Disease Among Adults with Underlying Chronic Conditions Post Implementation of PCV13 Immunization Programs in South Central Ontario, Canada. 12th International Symposium on Pneumococci and Pneumococcal Diseases; Toronto, Canada 2022.
6. LeBlanc JJ, ElSherif M, Ye L, MacKinnon-Cameron D, Ambrose A, Hatchette TF, et al. Recalibrated estimates of non-bacteremic and bacteremic pneumococcal community acquired pneumonia in hospitalized Canadian adults from 2010 to 2017 with addition of an extended spectrum serotype-specific urine antigen detection assay. *Vaccine*. 2022;40(18):2635-46.
7. Wijayasri S, Hillier K, Lim GH, Harris TM, Wilson SE, Deeks SL. The shifting epidemiology and serotype distribution of invasive pneumococcal disease in Ontario, Canada, 2007-2017. *PLOS ONE*. 2019;14(12):e0226353.
8. Shigayeva A, Rudnick W, Green K, Chen DK, Demczuk W, Gold WL, et al. Invasive Pneumococcal Disease Among Immunocompromised Persons: Implications for Vaccination Programs. *Clin Infect Dis*. 2016;62(2):139-47.
9. Backhaus E, Berg S, Andersson R, Ockborn G, Malmström P, Dahl M, et al. Epidemiology of invasive pneumococcal infections: manifestations, incidence and case fatality rate correlated to age, gender and risk factors. *BMC Infectious Diseases*. 2016;16(1):367.
10. Jit M. The risk of sequelae due to pneumococcal meningitis in high-income countries: A systematic review and meta-analysis. *Journal of Infection*. 2010;61(2):114-24.
11. Leidner AJ. Summary of three economic models assessing pneumococcal vaccines in US adults. Presentation to the Advisory Committee on Immunization Practices. 2021.
12. van Werkhoven CH, Huijts SM, Bolkenbaas M, Grobbee DE, Bonten MJM. The Impact of Age on the Efficacy of 13-valent Pneumococcal Conjugate Vaccine in Elderly. *Clinical Infectious Diseases*. 2015;61(12):1835-8.
13. Patterson S, Webber C, Patton M, Drews W, Huijts SM, Bolkenbaas M, et al. A post hoc assessment of duration of protection in CAPiTA (Community Acquired Pneumonia immunization Trial in Adults). *Trials in Vaccinology*. 2016;5:92-6.
14. O'Reilly R, Lu H, Kwong JC, McGeer A, To T, Sander B. The epidemiology and healthcare costs of community-acquired pneumonia in Ontario, Canada: a population-based cohort study. *J Med Econ*. 2023;26(1):293-302.
15. Canadian Institute for Health Information (CIHI). Data Quality Documentation, Discharge Abstract Database — Current-Year Information, 2015–2016 [Internet]. Ottawa (ON): CIHI; 2016 [cited 2023 Mar 31]. Available from: https://www.cihi.ca/sites/default/files/document/dad-data-quality_15-16_en.pdf.
16. Canadian Institute for Health Information (CIHI). Data Quality Documentation, Discharge Abstract Database - Current-Year Information, 2016–2017 [Internet]. Ottawa (ON): CIHI; 2017 [cited 2023 Mar 31]. Available from: https://www.cihi.ca/sites/default/files/document/current-year-information_dad_2016-2017-en-web.pdf.

17. Canadian Institute for Health Information (CIHI). Data Quality Documentation, Discharge Abstract Database - Current-Year Information, 2017–2018 [Internet]. Ottawa (ON): CIHI; 2018 [cited 2023 Mar 31]. Available from: <https://www.cihi.ca/sites/default/files/document/current-year-information-dad-2017-2018-en-web.pdf>.
18. Canadian Institute for Health Information (CIHI). Data Quality Documentation Discharge Abstract Database - Current-Year Information 2018–2019 [Internet]. Ottawa (ON): CIHI; 2019 [cited 2023 Mar 31]. Available from: <https://www.cihi.ca/sites/default/files/document/current-year-information-dad-2018-2019-en-web.pdf>.
19. Glauser W, Pendharkar S, Nolan M. Why do you have to pay for an ambulance? : healthydebate; 2015 [Available from: <https://healthydebate.ca/2015/07/topic/ambulance-fees/>].
20. Government of Northwest Territories. Visitors to the NWT Emergency Medical Travel [Internet]. 2018 [Available from: <https://www.hss.gov.nt.ca/sites/hss/files/resources/visitors-emergency-medical-travel.pdf>].
21. Government of Nunavut. Medical Travel - Medevac [Internet]. [Available from: <https://www.gov.nu.ca/health/information/medical-travel-medevac>].
22. Rendell M. City Brief: Should City Reduce Ambulance Fees? Edge North. 2016 March 22, 2016.
23. Tam DY, Banerji A, Paes BA, Hui C, Tarride J-E, Lanctôt KL. The cost effectiveness of palivizumab in term Inuit infants in the Eastern Canadian Arctic. *Journal of Medical Economics*. 2009;12(4):361-70.
24. Government of Yukon. Find out which medical travel costs our health plan covers [Available from: <https://yukon.ca/en/medical-treatment-travel>].
25. Pong RW, Pitblado JR. Geographic distribution of physicians in Canada: beyond how many and where. Ottawa, Ontario: Canadian Institute for Health Information,; 2005. Contract No.: ISBN 1-55392-736-2 (PDF).
26. Canada Revenue Agency. Reasonable per-kilometre allowance 2022 [Available from: <https://www.canada.ca/en/revenue-agency/services/tax/businesses/topics/payroll/benefits-allowances/automobile/automobile-motor-vehicle-allowances/reasonable-kilometre-allowance.html>].
27. Colbert Y. 'My jaw dropped,' says Ontario woman of \$12K air ambulance bill in Nova Scotia. *CBC News*. 2020 November 27, 2020.
28. Hollander MJ, Liu G, Chappell NL. Who cares and how much? The imputed economic contribution to the Canadian healthcare system of middle-aged and older unpaid caregivers providing care to the elderly. *Healthc Q*. 2009;12(2):42-9.
29. Wyrwich KW, Yu H, Sato R, Powers JH. Observational longitudinal study of symptom burden and time for recovery from community-acquired pneumonia reported by older adults surveyed nationwide using the CAP Burden of Illness Questionnaire. *Patient Relat Outcome Meas*. 2015;6:215-23.
30. Ganapathy V, Graham GD, DiBonaventura MD, Gillard PJ, Goren A, Zorowitz RD. Caregiver burden, productivity loss, and indirect costs associated with caring for patients with poststroke spasticity. *Clin Interv Aging*. 2015;10:1793-802.
31. Tyrrell G, Lee C, Eurich D. Is there a need for pneumococcal vaccination programs for the homeless to prevent invasive pneumococcal disease? *Expert Review of Vaccines*. 2021;20(9):1113-21.
32. Plevneshi A, Svoboda T, Armstrong I, Tyrrell GJ, Miranda A, Green K, et al. Population-based surveillance for invasive pneumococcal disease in homeless adults in Toronto. *PLoS One*. 2009;4(9):e7255.
33. Steinberg J, Bressler SS, Orell L, Thompson GC, Kretz A, Reasonover AL, et al. Invasive Pneumococcal Disease and Potential Impact of Pneumococcal Conjugate Vaccines Among Adults, Including Persons Experiencing Homelessness—Alaska, 2011–2020. *Clinical Infectious Diseases*. 2023;78(1):172-8.

34. Shariatzadeh MR, Huang JQ, Tyrrell GJ, Johnson MM, Marrie TJ. Bacteremic pneumococcal pneumonia: a prospective study in Edmonton and neighboring municipalities. *Medicine (Baltimore)*. 2005;84(3):147-61.
35. Lansbury L, Lim B, McKeever TM, Lawrence H, Lim WS. Non-invasive pneumococcal pneumonia due to vaccine serotypes: A systematic review and meta-analysis. *eClinicalMedicine*. 2022;44.
36. Government of Canada. Adult National Immunization Coverage Survey (aNICS): 2023 results. Ottawa, ON: Government of Canada; 2024.
37. Farrar JL, Childs L, Ouattara M, Akhter F, Britton A, Pilishvili T, Kobayashi M. Systematic Review and Meta-Analysis of the Efficacy and Effectiveness of Pneumococcal Vaccines in Adults. *Pathogens*. 2023;12(5).
38. Lewis N, Hsiao A, Hansen J, Yee A, Chao C, Suaya JA, et al. 2711. Effectiveness of 13-Valent Pneumococcal Conjugate Vaccine Against Invasive Pneumococcal Disease in Older Adults. *Open Forum Infectious Diseases*. 2019;6(Supplement_2):S953-S4.
39. Stoecker C. Economic analysis and public health impact of PCV21 in adults [slides presented at Advisory Committee on Immunization Practices (ACIP) meeting June 27, 2024][Internet]. Atlanta (GA): Center for Disease Control and Prevention; 2024 Jun 27 [cited TBD]. Available from: TBD.
40. Djennad A, Ramsay ME, Pebody R, Fry NK, Sheppard C, Ladhani SN, Andrews NJ. Effectiveness of 23-Valent Polysaccharide Pneumococcal Vaccine and Changes in Invasive Pneumococcal Disease Incidence from 2000 to 2017 in Those Aged 65 and Over in England and Wales. *eClinicalMedicine*. 2018;6:42-50.
41. Bonten MJM, Huijts SM, Bolkenbaas M, Webber C, Patterson S, Gault S, et al. Polysaccharide Conjugate Vaccine against Pneumococcal Pneumonia in Adults. *New England Journal of Medicine*. 2015;372(12):1114-25.
42. Stoecker C. Economic assessment of routine PCV20 for children [slides presented at Advisory Committee on Immunization Practices (ACIP) meeting June 22, 2023][Internet]. Atlanta (GA): Center for Disease Control and Prevention; 2023 Jun 22 [cited 2023 Jun 24]. Available from: <https://www.cdc.gov/vaccines/acip/meetings/downloads/slides-2023-06-21-23/02-Pneumococcal-Stoecker-508.pdf>.
43. Suaya JA, Jiang Q, Scott DA, Gruber WC, Webber C, Schmoele-Thoma B, et al. Post hoc analysis of the efficacy of the 13-valent pneumococcal conjugate vaccine against vaccine-type community-acquired pneumonia in at-risk older adults. *Vaccine*. 2018;36(11):1477-83.
44. O'Reilly R, Kwong JC, McGeer A, To T, Sander B. The Cost-Effectiveness of a Pneumococcal Conjugate Vaccine (PCV13) Program for Older Adults (65+) in Ontario, Canada: Update on the use of pneumococcal vaccine in immunocompetent adults 65 years of age and older – A Public Health Perspective in the Context of Infant Immunization and Changing Serotype Distributions. Society for Medical Decision Making 39th Annual North American Meeting (Poster Session 1) 2017 .
45. Pfizer Canada. Personal communication: PCV20 Canadian list price update. 2024.
46. Merck Canada Inc. Personal communication: Disclosure of V116 (PCV-21; PNEU-C-21) List Price for Economic Evaluation. 2024.
47. Christensen H, Trotter CL, Hickman M, Edmunds WJ. Re-evaluating cost effectiveness of universal meningitis vaccination (Bexsero) in England: modelling study. *BMJ*. 2014;349:g5725.
48. Ontario Ministry of Health. Ontario Drug Benefit Formulary/Comparative Drug Index [Internet]. 2022 [Available from: https://www.health.gov.on.ca/en/pro/programs/drugs/formulary43/edition_43.pdf].
49. Statistics Canada. Table 11-10-0239-01. Income of individuals by age group, sex and income source, Canada, provinces and selected census metropolitan areas [Internet]. Ottawa (ON): Statistics Canada; 2024 May 24 [cited 2024 May 24]. Available from: <https://doi.org/10.25318/1110023901-eng>.

50. Pasquale CB, Vietri J, Choate R, McDaniel A, Sato R, Ford KD, et al. Patient-reported consequences of community-acquired pneumonia in patients with chronic obstructive pulmonary disease. *Chronic Obstr Pulm Dis*. 2019;6(2):132-44.
51. Bizier C, Contreras R, Walpole A. Hearing disabilities among Canadians aged 15 years and older, 2012 [Internet]. Statistics Canada,; 2016 [
52. Jiang Y, Gauthier A, Annemans L, van der Linden M, Nicolas-Spony L, Bresse X. Cost-effectiveness of vaccinating adults with the 23-valent pneumococcal polysaccharide vaccine (PPV23) in Germany. *Expert Review of Pharmacoeconomics & Outcomes Research*. 2012;12(5):645-60.
53. Yan J, Xie S, Johnson JA, Pullenayegum E, Ohinmaa A, Bryan S, Xie F. Canada population norms for the EQ-5D-5L. *Eur J Health Econ*. 2023.
54. Mangen M-JJ, Huijts SM, Bonten MJM, de Wit GA. The impact of community-acquired pneumonia on the health-related quality-of-life in elderly. *BMC Infectious Diseases*. 2017;17(1):208.
55. Oppong R, Jit M, Smith RD, Butler CC, Melbye H, Mölsted S, Coast J. Cost-effectiveness of point-of-care C-reactive protein testing to inform antibiotic prescribing decisions. *Br J Gen Pract*. 2013;63(612):e465-e71.
56. Oppong R, Kaambwa B, Nuttall J, Hood K, Smith RD, Coast J. The impact of using different tariffs to value EQ-5D health state descriptions: an example from a study of acute cough/lower respiratory tract infections in seven countries. *The European Journal of Health Economics*. 2013;14(2):197-209.
57. Galante J, Augustovski F, Colantonio L, Bardach A, Caporale J, Marti SG, Kind P. Estimation and Comparison of EQ-5D Health States' Utility Weights for Pneumococcal and Human Papillomavirus Diseases in Argentina, Chile, and the United Kingdom. *Value in Health*. 2011;14(5, Supplement):S60-S4.